Abstract: SA-PO0124
Patients with Autosomal Dominant Tubulointerstitial Kidney Disease-Uromodulin (ADTKD-UMOD) Are at Increased Risk of Urinary Tract Infections (UTIs) and Patients with ADTKD-MUC1 Are at Increased Risk of Viral Lung Infections
Session Information
- ADPKD and Cystic Kidney Disease - 3
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Genetic Diseases of the Kidneys
- 1201 Genetic Diseases of the Kidneys: Cystic (Monogenic)
Authors
- Kidd, Kendrah O., Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
- Couch, Noah S., Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
- Zivna, Martina, Univerzita Karlova 1 lekarska fakulta, Prague, Czechia
- Kmoch, Stanislav, Univerzita Karlova 1 lekarska fakulta, Prague, Czechia
- Bleyer, Anthony J., Wake Forest University School of Medicine, Winston-Salem, United States
Background
Uromodulin has been shown to participate in host defense against UTIs and to prevent kidney stones. Mucin-1 also participates in host-defense in the respiratory and GU tract. Patients with ADTKD-UMOD (UMOD) or ADTKD-MUC1 (MUC1) make less than half the normal amount of uromodulin or mucin-1. Hypothesis: UMOD patients will be at increased risk of UTIs and kidney stones vs. controls and MUC1 patients will be at increased risk of pulmonary infections.
Methods
A survey was sent to 479 individuals with ADTKD as well as unaffected family members. 235 UMOD, 150 MUC1 and 94 unaffected family members answered the survey. Of ADTKD respondents, 31% UMOD and 48% MUC1 patients had been transplanted. Negative-binomial regression analysis was performed to compare survey results, while accounting for baseline characteristics.
Results
See Table 1 for results regarding non-ESRD patients. Non-ESRD UMOD patients were shown to have higher rates of UTI over the last year when compared to controls while controlling for age and gender (incidence rate ratio (IRR): 3.26, 95% CI [1.18, 9.61], p = 0.029). 4% of controls had a UTI within the last year vs. 16% of non-ESRD UMOD patients (p=0.009 vs. controls) and 12% of non-ESRD MUC1 patients (p=0.119 vs. controls). UMOD patients did not have an increased incidence of kidney stones. Non-ESRD MUC1 patients experienced COVID-19 more often than controls when controlling for age, gender, and vaccination status (IRR: 1.31, 95% CI [1.03, 1.68], p = 0.029). MUC1 patients also reported higher rates of Influenza compared to controls (IRR: 1.28, 95% CI [1.08, 1.52], p = 0.005) and UMOD patients (IRR: 1.22, 95% CI: [1.04, 1.42], p = 0.012) when controlling for age, gender, and vaccination status.
Conclusion
ADTKD-UMOD patients have an increased risk of UTIs vs. controls and ADTKD-MUC1 patients have an increased risk of pulmonary viral infections.
Survey results for non-ESRD patients
| Controls | ADTKD-UMOD | P-Value vs. controls | ADTKD-MUC1 | P-Value vs. controls | |
| UTIs per year in last year | 0.26(0.67) | 0.43(1.10) | 0.023 | 0.22(0.55) | 0.505 |
| UTIs per year in last 5 years | 0.09(0.41 | 0.27(0.75) | 0.115 | 0.30(1.20) | 0.075 |
| Lifetime kidney stones experienced (n) | 0.37(1.13) | 0.29(1.41) | 0.469 | 0.11(0.76) | 0.029 |
| Lifetime COVID-19 episodes (n) | 1.37(1.08) | 1.48(0.99) | 0.428 | 1.85(1.03) | 0.029 |
| Lifetime influenza episodes (n) | 3.0(3.4) | 2.9(3.2) | 0.529 | 3.3(3.4) | 0.005 |
| Colds experienced in last year (n) | 1.75(1.38) | 1.80(1.17) | 0.891 | 2.14(1.63) | 0.417 |
Mean(SD); P-Values calculated from negative binomial regression compared with controls
Funding
- Other U.S. Government Support